Qiao et al. demonstrated that PD-L2 plays a significant role in escaping from immune surveillance in patients with head and neck squamous cell carcinoma (HNSCC) by binding to PD-1-positive tumor-infiltrating lymphocytes (TILs). The gene discussed is PDCD1; the disease is neoplasm.